A review of interleukin-2 receptor antagonists in solid organ transplantation.

Article Details

Citation

Copy to clipboard

Berard JL, Velez RL, Freeman RB, Tsunoda SM

A review of interleukin-2 receptor antagonists in solid organ transplantation.

Pharmacotherapy. 1999 Oct;19(10):1127-37.

PubMed ID

10512062 [ View in PubMed

]

Abstract

Daclizumab and basiliximab, engineered human IgG monoclonal antibodies to the interleukin-2 (IL-2) receptor alpha-subunit, were approved to prevent acute rejection after renal transplantation. Daclizumab was studied in adult and pediatric renal allograft recipients, liver allograft recipients, and calcineurin-sparing protocols in renal transplant recipients. Basiliximab was studied in renal allograft recipients and subgroups of recipients of living-related and cadaveric transplants, and in patients with diabetes mellitus. Both agents reduced acute rejection and were associated with few adverse effects. However, information regarding their long-term effects on infection, malignancy, chronic rejection, and patient survival must be available before a final decision is made regarding their proper administration. We propose that a likely role the drugs will play in the field of solid organ transplantation is in new protocols that allow sparing of other more toxic immunosuppressive agents.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Basiliximab	Interleukin-2 receptor subunit alpha	Protein	Humans	Yes	Antibody	Details